Generate Biomedicines (GENB), a clinical-stage generative biology firm, said late Thursday it priced its initial public offering of 25 million common shares at $16 each.
IPO underwriters have a 30-day overallotment option to purchase up to 3.75 million additional shares.
The company expects its shares to start trading on the Nasdaq Global Select Market under the ticker symbol GENB Friday, while the IPO is expected to close Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.